Table S5 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma

Table S5 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma

<p>Statistics from DESeq2</p>

Shranjeno v:

Bibliografske podrobnosti
Glavni avtor:	Alyssa C. Flint (16676029) (author)
Drugi avtorji:	Dana K. Mitchell (16676032) (author), Steven P. Angus (15084264) (author), Abbi E. Smith (16676035) (author), Waylan Bessler (16676038) (author), Li Jiang (16676041) (author), Henry Mang (15293185) (author), Xiaohong Li (16676044) (author), Qingbo Lu (16676047) (author), Brooke Rodriguez (16676050) (author), George E. Sandusky (16676053) (author), Andi R. Masters (16676056) (author), Chi Zhang (15084270) (author), Pengtao Dang (16676059) (author), Jenna Koenig (16676062) (author), Gary L. Johnson (15081520) (author), Weihua Shen (16676065) (author), Jiangang Liu (15018711) (author), Amit Aggarwal (16610489) (author), Gregory P. Donoho (16676068) (author), Melinda D. Willard (16676071) (author), Shripad V. Bhagwat (16676074) (author), D. Wade Clapp (16676077) (author), Steven D. Rhodes (16676080) (author)
Izdano:	2025
Teme:	Cancer Molecular and Cellular Biology Therapeutic Research and Development Methods and Technology Cell Cycle CDKs and CDK inhibitors Chemotherapy Combination chemotherapy Gene Technologies High-throughput sequencing Preclinical Models Animal models of cancer Proteomics Rare Cancers Translational Research
Oznake:	Označite Brez oznak, prvi označite!

Podobne knjige/članki

Table S2 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
od: Alyssa C. Flint (16676029)
Izdano: (2025)

Figure S1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
od: Elizabeth R. Tucker (15053624)
Izdano: (2025)

Figure S2 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
od: Elizabeth R. Tucker (15053624)
Izdano: (2025)

Figure S3 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
od: Elizabeth R. Tucker (15053624)
Izdano: (2025)

Figure S4 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
od: Elizabeth R. Tucker (15053624)
Izdano: (2025)

Figure S5 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
od: Elizabeth R. Tucker (15053624)
Izdano: (2025)

Figure S6 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
od: Elizabeth R. Tucker (15053624)
Izdano: (2025)

Supplementary Table S2 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
od: Arun Kanakkanthara (14937731)
Izdano: (2025)

Supplementary Table S3 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
od: Arun Kanakkanthara (14937731)
Izdano: (2025)

Table S1 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
od: Xiaoqing Cheng (16918496)
Izdano: (2025)

Table S2 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
od: Xiaoqing Cheng (16918496)
Izdano: (2025)

Table S3 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
od: Xiaoqing Cheng (16918496)
Izdano: (2025)

Table S4 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
od: Xiaoqing Cheng (16918496)
Izdano: (2025)

Table S5 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
od: Xiaoqing Cheng (16918496)
Izdano: (2025)

Table S6 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
od: Xiaoqing Cheng (16918496)
Izdano: (2025)

Supplementary Tables from Biallelic <i>Dicer1</i> Mutations in the Gynecologic Tract of Mice Drive Lineage-Specific Development of <i>DICER1</i> Syndrome–Associated Cancer
od: Yemin Wang (17315078)
Izdano: (2025)

Supplementary Figure S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
od: Aurelius Omlin (14971513)
Izdano: (2025)

Supplementary Table S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
od: Aurelius Omlin (14971513)
Izdano: (2025)

Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
od: Dwight H. Owen (15034782)
Izdano: (2025)

Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
od: Dwight H. Owen (15034782)
Izdano: (2025)

Supplementary Figure 3 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
od: Dwight H. Owen (15034782)
Izdano: (2025)

Supplementary Figure 4 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
od: Dwight H. Owen (15034782)
Izdano: (2025)

Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
od: Dwight H. Owen (15034782)
Izdano: (2025)

Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
od: Evangeline R. Jackson (15558808)
Izdano: (2025)

Supplementary Tables from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
od: Craig M. Goodwin (14955973)
Izdano: (2025)

Figure S1 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
od: Craig M. Goodwin (14955973)
Izdano: (2025)

Figure S1 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
od: Craig M. Goodwin (14955973)
Izdano: (2025)

Figure S1 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
od: Craig M. Goodwin (14955973)
Izdano: (2025)

Figure S1 page4 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
od: Craig M. Goodwin (14955973)
Izdano: (2025)

Figure S2 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
od: Craig M. Goodwin (14955973)
Izdano: (2025)

Figure S2 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
od: Craig M. Goodwin (14955973)
Izdano: (2025)

Figure S2 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
od: Craig M. Goodwin (14955973)
Izdano: (2025)

Figure S3 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
od: Craig M. Goodwin (14955973)
Izdano: (2025)

Figure S3 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
od: Craig M. Goodwin (14955973)
Izdano: (2025)

Figure S4 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
od: Craig M. Goodwin (14955973)
Izdano: (2025)

Figure S4 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
od: Craig M. Goodwin (14955973)
Izdano: (2025)

Figure S5 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
od: Craig M. Goodwin (14955973)
Izdano: (2025)

Figure S5 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
od: Craig M. Goodwin (14955973)
Izdano: (2025)

Figure S5 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
od: Craig M. Goodwin (14955973)
Izdano: (2025)

Figure S5 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
od: Craig M. Goodwin (14955973)
Izdano: (2025)

Cannot write session to /tmp/vufind_sessions/sess_6jm1uaehab98m5ughim8cc12kk